John Currado’s GIST Surgery: A Patient’s Experience With Dr. Anton Bilchik
When John Currado, a prostate cancer survivor, began experiencing unusual fatigue, he had no reason to expect that another cancer diagnosis would follow. His experience would eventually involve two types of cancer, a rare gastrointestinal stromal tumor (GIST), targeted medication, and complex surgery performed by Anton Bilchik, MD, at Providence Saint John’s Health Center.
John’s story illustrates the importance of coordinated care among specialists and how targeted treatment can sometimes make surgery possible for patients with advanced gastrointestinal stromal tumors.
From Prostate Cancer to an Unexpected Diagnosis
John had previously received treatment for prostate cancer under the care of Jennifer Linehan, MD, and Timothy Wilson, MD, at Saint John’s. After reviewing his imaging and test results, his prostate cancer team recommended that he come directly to the hospital for evaluation by Dr. Bilchik, a gastrointestinal surgical oncologist and Chief of General Surgery at Providence Saint John’s Health Center.
While on a trip to San Francisco with his wife, John had awakened with an overwhelming wave of fatigue unlike anything he had previously experienced. He knew something was wrong. His medical evaluation would reveal that he was experiencing anemia, a condition that can cause significant weakness and fatigue.
Further testing identified an advanced gastrointestinal stromal tumor involving his stomach, with cancer that had spread to his liver. In late 2017, John was diagnosed with what the original account described as stage IV GIST, and his physicians began developing a treatment plan.
GIST is a rare type of tumor that develops in the digestive tract and behaves differently from the more common cancers that arise from the stomach lining. In John’s case, the disease required an approach that combined targeted medication with specialized surgical care.
John Currado Shares His Cancer Experience
In his original patient testimonial, John describes the unexpected diagnosis, his treatment at Saint John’s, and the experience of working with Dr. Bilchik and his medical team.
Listen to John Currado’s Cancer Story
Targeted Therapy Before Surgery
Because John’s tumors involved both his stomach and liver, his physicians initially treated him with Gleevec (imatinib), an oral targeted medication used for certain gastrointestinal stromal tumors. Imatinib works by blocking specific proteins involved in the growth of many GISTs.
The purpose of treatment was to reduce the extent of his tumors and determine whether surgery could become an option. This approach, in which medication is given before a planned operation, is commonly described as neoadjuvant therapy. In patients with metastatic GIST, targeted therapy is also used to control disease, with surgery considered selectively according to treatment response and other factors.
John took imatinib daily for approximately 11 months. During that period, the tumors in his stomach and liver responded sufficiently for his medical team to proceed with surgery.
Complex GIST Surgery at Saint John’s Health Center
In November 2018, Dr. Bilchik and his surgical team performed two procedures during an operation lasting approximately seven and a half hours. The surgery included removal of approximately 15 percent of John’s stomach and the right lobe of his liver, which contained a tumor described in the original account as weighing seven pounds.
The surgeons also removed additional tumor deposits from the area surrounding the vena cava, a major vein that carries blood back to the heart. These procedures required careful planning because of the tumors’ locations and their relationship to important blood vessels and surrounding organs.
Following removal of part of the liver, the remaining liver tissue can increase in size and functional capacity over time. This regenerative ability is one reason selected patients can undergo liver resection, although the amount of healthy liver remaining and the patient’s overall liver function are important considerations.
John spent approximately one week in the hospital recovering from surgery. He reported experiencing no postoperative pain during that recovery period. His experience was favorable in this respect, although recovery after major gastrointestinal and liver surgery varies considerably among patients.
At the time the original story was published in December 2021, John and his wife were living in Lancaster, California. He continued to return to Saint John’s for follow-up appointments and was still receiving imatinib. His story documents an important period in his treatment and recovery rather than establishing his current medical status.
Understanding Gastrointestinal Stromal Tumors (GISTs)
Gastrointestinal stromal tumors are uncommon tumors that develop from specialized cells in the digestive tract or related precursor cells. They are generally classified as a type of soft tissue sarcoma and are biologically distinct from gastric adenocarcinoma, the most common form of stomach cancer.
GISTs most frequently occur in the stomach or small intestine, although they can arise elsewhere along the gastrointestinal tract. Some remain small and cause no symptoms, while others grow, bleed, or spread to other parts of the body, particularly the liver or abdominal lining.
The diagnosis and treatment of GIST depend on tumor size, location, growth characteristics, molecular findings, and whether the disease has spread.
How Are GISTs Different From Other Stomach Cancers?
Most stomach cancers develop from glandular cells in the stomach lining. GISTs arise from a different type of cell associated with the muscular wall of the gastrointestinal tract. This difference affects how the tumors grow, how they spread, and which treatments are most effective.
GISTs frequently contain changes in genes such as KIT or PDGFRA. These changes can influence whether a tumor responds to particular targeted medications. Conventional chemotherapy, commonly used for gastric adenocarcinoma, generally has little effectiveness against GIST.
Because GIST is a distinct diagnosis, patients should not assume that screening recommendations, surgical approaches, or treatment plans for conventional stomach cancer apply in the same way.
What Symptoms Can a GIST Cause?
Some gastrointestinal stromal tumors are discovered unexpectedly during imaging, endoscopy, or surgery performed for another reason. Others cause symptoms related to tumor size, location, bleeding, or pressure on nearby structures.
Possible symptoms include:
- Unexplained fatigue or weakness, sometimes associated with anemia
- Blood in the stool or gastrointestinal bleeding
- Abdominal pain, pressure, or discomfort
- Feeling full after eating a small amount
- Nausea or vomiting
- Difficulty swallowing when a tumor affects the upper digestive tract
These symptoms have many possible causes and do not necessarily indicate GIST. However, significant anemia, gastrointestinal bleeding, or persistent unexplained symptoms deserve medical evaluation. Severe bleeding or rapidly worsening symptoms may require urgent care.
How Are GISTs Diagnosed?
Evaluation may involve CT or MRI imaging, endoscopy, endoscopic ultrasound, and tissue sampling when appropriate. A pathologist examines the tumor to determine whether its characteristics are consistent with GIST. Specialized testing may include markers such as KIT (CD117) and DOG1.
Molecular testing can identify changes in KIT, PDGFRA, or other genes that may influence treatment. The diagnostic approach depends on the tumor’s location, whether surgery is planned, and whether tissue is needed before starting systemic therapy.
How Are Gastrointestinal Stromal Tumors Treated?
GIST treatment differs from conventional stomach cancer treatment. Surgery may be the primary treatment when a localized tumor can be removed safely. For tumors that cannot initially be removed, have spread to other organs, or carry a significant risk of recurrence, targeted medications may play an important role.
Surgery for Localized GIST
For many localized, resectable GISTs, surgery is the principal treatment. The goal is to remove the tumor while preserving surrounding structures when possible and avoiding rupture of the tumor during the operation.
Unlike many gastric adenocarcinomas, GISTs generally do not require extensive lymph node removal because spread to nearby lymph nodes is uncommon. The amount of stomach or other digestive tissue removed depends on the tumor’s size and location.
Targeted Treatment With Imatinib and Other Medications
Imatinib is an important treatment for many GISTs containing molecular changes that make them sensitive to the medication. It may be used before surgery to shrink a tumor, after surgery to reduce recurrence risk in selected high-risk patients, or as ongoing treatment for certain unresectable or metastatic tumors.
Not all GISTs respond to imatinib. For example, tumors with a PDGFRA D842V mutation are generally resistant to imatinib and may respond to a different medication, avapritinib. Other targeted medications, including sunitinib, regorafenib, and ripretinib, may be used in appropriate settings when earlier treatment is ineffective or cannot be tolerated.
Molecular testing is therefore important in determining which treatment is most suitable. The choice of medication, its duration, and how patients are monitored depend on their individual disease characteristics.
When Is Surgery Considered for Metastatic GIST?
When GIST has spread to the liver or other sites, targeted drug therapy is generally central to treatment. Surgery may also be considered for carefully selected patients, particularly when the disease has responded to medication, remains controlled, and the affected areas can be addressed safely.
The potential role of surgery depends on the location and number of tumors, response to targeted therapy, overall health, and whether removing the tumors is likely to provide meaningful clinical benefit. Surgery is not routinely recommended for every patient with metastatic GIST, and its benefits in this setting remain subject to clinical uncertainty.
John’s treatment illustrates one selected approach in which targeted therapy reduced tumor burden sufficiently for extensive surgery to be undertaken. His experience should not be interpreted as the expected course for every person with advanced GIST.
Living With GIST: Treatment, Monitoring, and Follow-Up
Patients with GIST may require ongoing imaging, specialist appointments, and monitoring for treatment-related side effects or cancer recurrence. Follow-up plans vary according to tumor size, growth characteristics, location, molecular findings, previous treatment, and the presence or absence of metastatic disease.
For patients receiving targeted therapy, the care team monitors treatment response and possible side effects. Medication may continue for an extended period when clinically appropriate. Patients should discuss any concerns about treatment tolerance, interruptions, or medication changes with their oncology team rather than stopping therapy independently.
Supportive services can also help address nutrition, recovery after abdominal surgery, emotional well-being, and the practical challenges of living with cancer. Learn more about Cancer Support Services at Providence Saint John’s Health Center.
Coordinated Care for Complex Gastrointestinal Tumors
John Currado’s experience demonstrates how coordinated medical care, targeted therapy, and specialized surgery can come together in the treatment of a complex gastrointestinal stromal tumor. His story is one patient’s experience, but it highlights the importance of understanding the tumor’s biology and considering treatment options through a multidisciplinary approach.
For more information about gastrointestinal tumors and individualized treatment planning, visit our Center for Gastrointestinal and Hepatobiliary Tumors. You can also explore our Stomach Cancer Conditions and Stomach Cancer Treatment pages for information about other types of stomach cancer and their care.
Sources & Further Reading
- National Cancer Institute — Gastrointestinal Stromal Tumors Treatment (Patient Version)
- National Cancer Institute — Gastrointestinal Stromal Tumors Treatment (Health Professional Version)
- Saint John’s Cancer Institute — Center for Gastrointestinal and Hepatobiliary Tumors
